Every Form 4 that Tharimmune, Inc. (THAR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow THAR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full THAR filings page.
Canton Strategic Holdings, Inc. director Gary S. Stetz reported open-market sales of company Common Stock. He sold a total of 100,351 shares in multiple transactions on May 22, 2026 and May 26, 2026 at prices ranging from $3.40 to $3.47 per share. After these sales, he directly owns 134,175 shares of Canton Strategic Holdings Common Stock.
Tharimmune (THAR) reported an insider equity award. A director and COO received a stock option grant for 5,000 derivative securities on 11/03/2025 with an exercise price of $3.075 per share. The option is first exercisable on 11/03/2025 and expires on 11/03/2035.
Following the reported transaction, the insider beneficially owned 55,000 derivative securities. The filing lists the ownership form as direct and records the transaction code as an acquisition.
Tharimmune, Inc. (THAR) reported insider activity on a Form 4. Director James Liddy received a stock option grant for 5,000 derivative securities on 11/03/2025 at an exercise price of $3.075 per share. The options are exercisable on 11/03/2025 and expire on 11/03/2035, covering underlying Common Stock (5,000 shares). Following this transaction, Liddy beneficially owns 55,000 derivative securities. The ownership form is reported as Direct (D).
Tharimmune (THAR) insider Vincent LoPriore filed a Form 4 reporting a grant of 90,000 stock options at an exercise price of $3.075 on 11/03/2025. The options are exercisable on 11/03/2025 and expire on 11/03/2035.
Following the transaction, LoPriore beneficially owned 190,000 derivative securities, held directly. He is listed as Executive Chairman, Director, and a 10% Owner.
Tharimmune (THAR) reported a director stock option grant. On 11/03/2025, a stock option for 5,000 shares was acquired at an exercise price of $3.075. The option is exercisable on 11/03/2025 and expires on 11/03/2035.
Following the transaction, 55,000 derivative securities were beneficially owned, held directly. The grant price of the derivative security was listed as $0.
Tharimmune (THAR) reported a director stock option grant on a Form 4. On 11/03/2025, the insider received 32,500 stock options at an exercise price of $3.075 per share, expiring on 11/03/2035. Following this grant, the insider beneficially owns 82,500 derivative securities, held direct.
Tharimmune (THAR) reported insider activity on a Form 4. A company director reported acquiring 90,000 stock options on 11/03/2025 at an exercise price of $3.075 per share. The options are first exercisable on 11/03/2025 and expire on 11/03/2035.
Following the transaction, the filing lists 190,000 derivative securities beneficially owned. The ownership is marked as Indirect (I), with a footnote referencing relationships among Gravitas Capital LP, Gravitas Capital Partners LLC, and Vincent S. LoPriore. This filing records the insider’s equity-linked position and timing terms.
Tharimmune (THAR) director Clay Kahler filed a Form 4 reporting a stock option grant. On 11/03/2025, he was awarded 17,500 stock options with a $3.075 exercise price, exercisable on 11/03/2025 and expiring on 11/03/2035.
Following the transaction, Kahler beneficially owned 67,500 derivative securities, held directly. The filing reflects routine equity compensation for a board member.
Tharimmune (THAR) CEO and director Sireesh Appajosyula reported a stock option grant for 20,000 shares at an exercise price of $3.075 on 11/03/2025.
The options are exercisable on 11/03/2025 and expire on 11/03/2035. Following the grant, the filing lists 225,962 derivative securities beneficially owned, held direct. No non‑derivative transactions were reported in Table I.